Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mibavademab - Regeneron Pharmaceuticals

Next Previous
X
Search
Drug Profile

Mibavademab - Regeneron Pharmaceuticals

Alternative Names: REGN-4461

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Monoclonal antibodies; Obesity therapies
  • Mechanism of Action Leptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lipodystrophy; Obesity

Most Recent Events

  • 16 Aug 2024 Regeneron Pharmaceuticals plans a phase III trial for Lipodystrophy (In adolescents, In adults, In children, In the elderly) in December 2024 (IV, SC) (NCT06548100)
  • 06 Jun 2024 Regeneron Pharmaceuticals terminates a phase-II trial in Lipodystrophy in France, Spain, Turkey and USA (SC) (NCT05088460) (EudraCT2021-000138-33)
  • 24 Apr 2024 Phase-II clinical trials in Obesity (Combination therapy) in USA (SC) (NCT06373146)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top